Wegovy HD 7.2 mg: what FDA approved
FDA approved Wegovy HD (semaglutide 7.2 mg weekly) on March 19, 2026 for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss.
Key takeaways
- Approved March 19, 2026, 54 days after filing, under FDA's National Priority Voucher pilot.
- 7.2 mg once weekly, only after at least 4 weeks on 2.4 mg when more weight loss is clinically indicated.
- Altered skin sensation was reported more often at 7.2 mg; FDA says it is investigating further.
The FDA approved Wegovy HD, a 7.2 mg once-weekly dose of semaglutide, on March 19, 2026. The agency says the decision came 54 days after filing and was the fourth approval under the Commissioner’s National Priority Voucher pilot program.
Where it sits in the schedule
The standard Wegovy label escalates over 16 weeks — 0.25, 0.5, 1 and 1.7 mg, four weeks each — to a 2.4 mg maintenance dose. Wegovy HD is an optional further step for adults who have been on 2.4 mg for at least four weeks and need more weight loss. Our semaglutide 2.4 mg label schedule lays out every step with the label link.
What the data showed
According to the FDA, the higher dose produced additional average weight reduction compared with earlier doses, with a safety profile consistent with semaglutide. In people with obesity and type 2 diabetes, A1C lowering was similar to the lower dose. Gastrointestinal effects were the most common. Reports of altered skin sensation — sensitivity, pain or burning — were more frequent at the higher dose and generally resolved on their own or with dose reduction.
How it compares
With Wegovy HD, the gap between semaglutide and tirzepatide’s 15 mg maximum is narrower than the original STEP 1 vs SURMOUNT-1 comparison suggests. See semaglutide vs tirzepatide and the semaglutide profile.
What the evidence does not show
- Long-term outcomes specific to the 7.2 mg dose beyond the submitted trial data.
Frequently asked questions
What is Wegovy HD?
A higher, 7.2 mg once-weekly dose of semaglutide approved by the FDA on March 19, 2026 for weight reduction and long-term maintenance in certain adults.
Who can use Wegovy HD?
Per the approval, adults with obesity, or overweight with at least one weight-related condition, after tolerating 2.4 mg for at least 4 weeks when additional weight loss is clinically indicated.
Is Wegovy HD the same drug as Ozempic?
Both contain semaglutide, but they are different products with different approved indications and doses.
Sources
Find a clinic
Our clinic directory lists only clinics whose address and services we confirmed on their own websites, with the date we checked.